Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $62,561.20 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 2,270 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total value of $62,561.20. Following the completion of the transaction, the chief executive officer now directly owns 1,061,255 shares of the company’s stock, valued at $29,248,187.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.92, for a total value of $299,040.00.
• On Tuesday, June 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.66, for a total value of $259,920.00.
• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $23.18, for a total value of $278,160.00.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $23.22 on Monday. The business’s fifty day moving average is $22.82 and its 200 day moving average is $19.68. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67. The company has a market capitalization of $1.09 billion, a PE ratio of -12.03 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. SG Americas Securities LLC grew its stake in shares of Enliven Therapeutics by 17.8% during the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics in the 4th quarter worth $66,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the period. AJOVista LLC bought a new stake in shares of Enliven Therapeutics in the fourth quarter worth about $28,000. Finally, EntryPoint Capital LLC purchased a new position in Enliven Therapeutics during the 1st quarter valued at about $167,000. 95.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company. Robert W. Baird began coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target for the company. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.